Irene Wang, PhD

Irene Wang, PhD

President
Lin BioScience

 

 

 

 

 

 

Dr. Irene Wang is currently President & R&D Director at Lin Bioscience, where she leads the company’s global R&D and collaborations with the NIH Blueprint Program, that has awarded over USD 10 million in funding towards developing the company’s first-in-class oral drug for the treatment of dry Age-Related Macular Degeneration. Over her career, Dr. Wang has led several drug development programs from drug discovery to global Phase 3 development in a wide range of therapeutic areas that includes ophthalmology, oncology, cardiovascular, and metabolic disease indications, by focusing on diseases of unmet medical need. Dr. Wang currently holds more than 30 new drug patents, has a successful track record in taking start-up biotech companies to IPO, and recently, she has been selected as one of the women leaders in biotech by Johnson & Johnson Innovations.